Confusion Persists Over US Biosimilar Interchangeability
Urgent Need For Clarity Over Misperceptions Linked To Unique US Designation, Paper Insists
Executive Summary
The US biosimilars industry is being constrained by misunderstandings stemming from the country’s interchangeability designation, a new paper in BioDrugs has highlighted, citing an urgent need for clarity over the misperception that interchangeable biosimilars are superior to biosimilars without the designation.
You may also be interested in...
Biosimilars Forum Calls For Further Action On Biden’s Competition Order
Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.
US Aspart Filing Kicks Off Amphastar’s Insulin Ambitions
Amphastar says a “milestone” submission of a US filing for insulin aspart underlines its ambitions in the diabetes segment. But could the firm get the first US biosimilar approval?
Celltrion Takes Aim At US Infliximab Market With Subcutaneous Launch
Celltrion has delivered on its long-awaited US launch of its Zymfentra subcutaneous formulation of infliximab, sold in other territories as Remsima SC.